Metabolic & Obesity Deal Benchmarks 2026

Median Upfront

$935M

Range: $509M - $1.4B

Total Deal Value

$4.5B

Range: $2.9B - $6.1B

Royalty Rate

16.1% - 29.5%

Tiered up to 33.5%

Dev Milestones

$647M

Range: $438M - $857M

Model Your Deal

Market Analysis

The metabolic/obesity therapeutic area has become the most commercially valuable segment in biopharma. Semaglutide (Wegovy/Ozempic) became the fastest drug to $20B annual revenue in pharma history, while tirzepatide (Mounjaro/Zepbound) demonstrated 22.5% weight loss — competitive with bariatric surgery.

Obesity licensing deals in 2025 have reached unprecedented levels. The AstraZeneca/CSPC deal at $18.5B headline value and Pfizer/Metsera at $9.8B demonstrate the massive premiums pharma companies are willing to pay for differentiated metabolic assets. Oral formulations, dual/triple incretins, and muscle-sparing approaches command the highest deal values.

GLP-1 obesity deals at Phase 2 typically command $935M upfront (range $509M - $1.4B), while oral peptide assets attract $1.1B upfront reflecting the oral delivery premium. NASH/MASH assets following resmetirom's approval see $654M upfront.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How much are GLP-1 obesity licensing deals worth in 2026?

Phase 2 GLP-1 agonist deals for obesity typically have total deal values of $2.9B - $6.1B, with upfronts of $935M. Oral formulations command 20-30% premiums over injectable equivalents.

What royalty rates do metabolic deals command?

Base royalties for metabolic deals range from 16.1% to 29.5%, tiering up to 33.5% at peak sales. The enormous commercial potential of obesity drugs drives aggressive tiered royalty structures.

How do oral obesity drug deals compare to injectables?

Oral metabolic drugs command significant premiums. Oral peptide deals average $5.1B total deal value vs $4.5B for injectable GLP-1s. The oral convenience advantage drives patient preference, primary care adoption, and payer formulary access.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Metabolic & Obesity Deal Benchmarks 2026

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

GLP-1 Obesity Deal Benchmarks

Dual & Triple Incretin Deals

NASH/MASH Deal Benchmarks

Oral Peptide Deal Benchmarks

Ready to Calculate Your Deal Terms?